Bone Biologics moved its annual meeting from August 11 to September 28, 2026, and expanded the ballot from three proposals to six. Shareholders will vote on potential warrant-related common stock issuance, a discretionary 1-for-2 to 1-for-10 reverse stock split, executive compensation, directors, auditor ratification and possible adjournment.

Key Highlights

  • Jeffrey Frelick’s total compensation rose to $426,269 in 2025 from $384,897 in 2024.
  • Executive compensation will face an advisory, non-binding Shareholder vote.
  • The meeting will take place at 11:30 a.m. Eastern Time at Bone Biologics’ Burlington, Massachusetts offices.

Bone Biologics Corp (NASDAQ: BBLGW) will ask shareholders to vote on six proposals at its annual meeting on September 28, 2026, including potential common stock issuance tied to certain warrants and a proposed reverse stock split. The meeting was postponed from August 11, 2026. The company added three proposals to the original ballot, including a possible adjournment if votes or a quorum are insufficient.

Six Proposals On Ballot

Shareholders will vote on four director seats. They will also consider the non-binding executive compensation proposal and the auditor ratification measure.

The fourth proposal seeks approval, for purposes of Nasdaq Listing Rule 5635(d), of potential issuance of common stock underlying certain warrants issued under a Securities Purchase Agreement dated July 7, 2026. The sixth proposal would allow the meeting to be adjourned if necessary or appropriate because there are not enough votes to approve the proposals or establish a quorum.

Executive Pay Figures

Frelick’s total compensation was $426,269 in 2025, consisting of $300,000 in salary, $26,269 in option awards and $100,000 in non-equity incentive plan compensation.

Walsh received total compensation of $263,136 in 2025. Her package included $200,000 in salary, $13,136 in option awards and $50,000 in non-equity incentive plan compensation.

The company’s annual performance-based cash award program uses company and individual performance metrics established by the Compensation Committee and the Board of Directors. For 2025, those awards included $100,000 in cash for Frelick and $50,000 for Walsh, while Frelick also received Options to purchase 16,668 shares of common stock.

The proxy materials show 2024 total compensation of $384,897 for Frelick and $242,448 for Walsh. The 2024 figures included $300,000 and $200,000 in salary, respectively, along with option awards of $30,788 and $15,394 and non-equity incentive compensation of $54,109 and $27,054.

September Shareholder Decisions

The warrant-related proposal is tied to compliance with Nasdaq Listing Rule 5635(d) and concerns potential issuance of common stock underlying certain warrants. The adjournment proposal addresses the possibility that the meeting lacks sufficient votes for the proposals or a quorum.

The executive compensation vote is advisory and non-binding. The annual meeting is scheduled for September 28, 2026, at Bone Biologics’ Burlington offices.